Hoff P T, Tamura Y, Lucchesi B R
Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-0626.
Am J Cardiol. 1989 Nov 7;64(17):101I-115I discussion 115I-116I. doi: 10.1016/0002-9149(89)90967-3.
Amlodipine is a dihydropyridine derivative belonging to the group of pharmacologic calcium entry blocking agents and is characterized as having a slow onset and relatively long duration of action with minimal effects on cardiac electrophysiology and myocardial contractility. The protective effect of amlodipine was studied in isolated blood-perfused feline hearts made globally ischemic for 60 minutes followed by reperfusion for 60 minutes. Ischemic-induced alterations of left ventricular developed pressure and complicance were monitored. In 11 control and 7 drug-treated hearts, amlodipine produced significant decreases in myocardial oxygen consumption (6.2 +/- 0.4 to 4.4 +/- 0.4 ml oxygen/min/100 g) and coronary vascular resistance, as assessed by changes in perfusion pressure (120 +/- 1 to 100 +/- 4 mm Hg). Amlodipine administered before the onset of global ischemia decreased the development of ischemic contracture as reflected by a progressive increase in resting left ventricular diastolic pressure. The return of contractile function, 60 minutes afer reperfusion, improved significantly in the amlodipine-treated group compared with controls, and there was better maintenance of the tissue concentration of Na+, Ca2+ and K+. A canine model of regional myocardial ischemia (90 minutes) followed by 6 hours of reperfusion was used to assess the cardioprotective effects of amlodipine, 150 micrograms/kg, administered 15 minutes before reperfusion. Infarct size, expressed as a percentage of the area at risk, was smaller in the amlodipine-treated group (n = 10) than in the control group (n = 10) (34.5 +/- 3.8% vs 45.9 +/- 2.8%, p = 0.027). Risk region size did not differ between groups and both groups were comparable with respect to the hemodynamic parameters of heart rate, blood pressure and rate-pressure product. Amlodipine prevented the gradual reduction in coronary blood flow observed in the control group. It is concluded that amlodipine reduces myocardial ischemic injury by mechanism(s) that may involve a reduction in myocardial oxygen demand as well as by positively influencing transmembrane Ca2+ fluxes during ischemia and reperfusion.
氨氯地平是一种二氢吡啶衍生物,属于药理钙通道阻滞剂类,其特点是起效缓慢、作用持续时间相对较长,对心脏电生理和心肌收缩力影响极小。在离体血液灌注的猫心脏上研究了氨氯地平的保护作用,使心脏整体缺血60分钟,随后再灌注60分钟。监测缺血诱导的左心室舒张末压和顺应性的变化。在11个对照心脏和7个药物处理的心脏中,氨氯地平使心肌耗氧量(从6.2±0.4降至4.4±0.4 ml氧/分钟/100 g)和冠状动脉血管阻力显著降低,灌注压力变化评估显示(从120±1降至100±4 mmHg)。在整体缺血开始前给予氨氯地平可减少缺血性挛缩的发展,这表现为静息左心室舒张压逐渐升高。再灌注60分钟后,氨氯地平治疗组的收缩功能恢复与对照组相比有显著改善,并且Na⁺、Ca²⁺和K⁺的组织浓度维持得更好。使用犬局部心肌缺血(90分钟)随后再灌注6小时的模型来评估氨氯地平在再灌注前15分钟给予150微克/千克的心脏保护作用。以危险区域面积的百分比表示的梗死面积,氨氯地平治疗组(n = 10)比对照组(n = 10)小(34.5±3.8%对45.9±2.8%,p = 0.027)。两组间危险区域大小无差异,且两组在心率、血压和心率 - 血压乘积的血流动力学参数方面具有可比性。氨氯地平阻止了对照组中观察到的冠状动脉血流的逐渐减少。得出的结论是,氨氯地平通过可能涉及降低心肌需氧量以及在缺血和再灌注期间对跨膜Ca²⁺通量产生积极影响的机制来减少心肌缺血损伤。